CXCL8 and B-cell chronic lymphocytic leukemia: reported that in some patients with chronic lymphocytic leukemia, the first administration of obinutuzumab directly released proinflammatory cytokines IL-6 and IL-8, and immune-mediated platelet lysis via CD20 antigen presentation or complement activation by circulating soluble CD20 antigen resulted in acute thrombocytopenia (5).